Corcept Therapeutics Inc (CORT) 3.43 $CORT
Moving Average Crossover Alert: Corcept Therapeutics (CORT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:27AM CST
Moving Average Crossover Alert: Corcept Therapeutics (CORT)
CORT: 3.43 (+0.03)
Global Cushing's Syndrome Therapeutics Market 2015-2019: Key Vendors are Corcept Therapeutics, HRA Pharma and Novartis
M2 - Thu Nov 20, 5:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvdxbs/global_cushings) has announced the addition of the "Global Cushing's Syndrome Therapeutics Market 2015-2019" report to their offering. One major trend upcoming in this market is the increase in public awareness of Cushing's syndrome. This is expected to lead to an increase in the number of treatment-seeking patients, thereby giving rise to the consumption of medications. According to the report, the major driving factor of the market is the presence of a huge unmet need in this rare disease area. Few FDA-approved drugs are available, and the use of off-label drugs can cause several adverse effects. Thus, drug makers have the opportunity to produce therapies which can give them an edge over others and seize a major portion of the total market. Further, the report states that the adverse effects of the drugs used to treat Cushing's syndrome are a major challenge to the growth of the market. Patient incompatibility leads to an increase in the churn-out rate of the patients from the treatment. This results in restraining the market growth. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Disease Overview 08. Market Landscape 09. Market Segmentation by Class of Drugs 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Form 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Pipeline Portfolio 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Corcept Therapeutics - HRA Pharma - Novartis - Aspireo Pharmaceuticals - Cortendo - ElexoPharm - Ipsen - Isis Pharmaceuticals - Orphagen Pharmaceuticals - Samaritan Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wv...l_cushings
ISIS: 62.32 (+0.45), CORT: 3.43 (+0.03), NVS: 93.52 (-0.82)
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:18PM CST
CORT: 3.43 (+0.03)
Corcept posts 3Q loss
Automated Insights - Tue Nov 04, 5:15PM CST
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported a loss of $6 million in its third quarter.
CORT: 3.43 (+0.03)
Corcept Therapeutics beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:28PM CST
CORT: 3.43 (+0.03)
Corcept Therapeutics Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Marketwired - Tue Nov 04, 3:09PM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today reported its financial results for the quarter ended September 30, 2014. The company also provided an update on its clinical programs and revised its 2014 revenue guidance.
CORT: 3.43 (+0.03)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.26 (-0.13), ITRI: 39.98 (-0.70), AWAY: 30.19 (+0.29), OKE: 44.86 (-0.81), HR: 27.04 (-0.01), NYMT: 7.82 (-0.08), OCLR: 1.89 (-0.01), ENPH: 12.45 (-0.10), ADEP: 8.14 (+0.02), CBSO: 27.51 (+0.58), NSTG: 13.58 (+0.27), MITT: 19.29 (-0.22), CRTO: 38.00 (-0.08), FOXA: 36.90 (-0.22), OKS: 39.41 (-0.11), JMBA: 13.62 (+0.09), IVR: 15.74 (-0.17), CSU: 24.93 (-0.29), MYGN: 33.98 (-1.15), JIVE: 5.76 (-0.09), GAS: 51.18 (-1.43), COUP: 15.00 (-0.27), NRP: 9.22 (-0.37), MOSY: 1.73 (-0.02), COHR: 58.29 (-0.85), DOX: 46.10 (-1.00), CKEC: 26.46 (-0.09), OAS: 12.33 (+1.28), PAYC: 24.46 (-1.18), PCYC: 132.65 (-2.34), AXLL: 38.92 (-2.19), NP: 57.25 (-0.95), BIRT: 6.54 (-0.01), ATVI: 19.90 (-0.44), EXAM: 39.18 (-0.36), P: 17.35 (-0.12), JAZZ: 165.12 (-8.09), PBPB: 12.11 (-0.13), EXEL: 1.40 (unch), CERS: 4.87 (+0.27), DVN: 53.01 (-0.83), FEYE: 29.12 (-0.32), CHUY: 19.81 (+0.34), FRGI: 62.85 (+1.60), GHDX: 32.13 (-0.53), PACD: 4.41 (-0.14), BIO: 117.51 (-1.55), BIOL: 2.74 (+0.06), JKHY: 61.51 (-0.38), KAR: 34.25 (+0.05), CDXS: 2.35 (+0.02), MPO: 1.07 (-0.23), FANG: 52.47 (-0.64), CORT: 3.43 (+0.03), CALD: 15.16 (-0.28)
Corcept reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:56PM CDT
CORT: 3.43 (+0.03)
Corcept Therapeutics to Announce Third Quarter Financial Results and Host Conference Call
Marketwired - Tue Oct 28, 3:08PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT: 3.43 (+0.03)
Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 3.49 (+0.03), AMPE: 3.66 (+0.15), CEMP: 19.00 (+0.47), CORT: 3.43 (+0.03)
Heartbeat Wins 8 New Awards, Including CLIO Silver & MM&M Gold
Business Wire - Mon Oct 13, 11:01AM CDT
Heartbeat Ideas and Heartbeat West, natively-digital, full-service, marketing innovation agencies, have won eight new awards over the last few weeks, bringing to 16 the total number of industry awards in this record-setting year for the company. Heartbeat's honored work includes Corcept Therapeutics' Korlym "Cushing's Connection" Integrated Campaign, XenoPort's HORIZANT "End the Bedtime Battle" Integrated Campaign, and Sientra's "Feel So Good" Online Media Campaign.
CORT: 3.43 (+0.03)
Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:48AM CDT
Esperion Therapeutics has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ESPR: 37.48 (-1.00), AMPE: 3.66 (+0.15), CEMP: 19.00 (+0.47), CORT: 3.43 (+0.03)
PTC Therapeutics (PTCT) Crumbles: Stock Falls by 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:42AM CDT
PTC Therapeutics stock fell over 5% last trading session, continuing its recent downtrend
LCI: 43.58 (-0.46), PTCT: 55.87 (+0.54), CEMP: 19.00 (+0.47), CORT: 3.43 (+0.03)
Publicis Healthcare Agencies and Leaders Honored at the 2014 MM&M Awards
PRWeb - Mon Oct 06, 7:04AM CDT
Publicis Healthcare Communications Group (PHCG), the world's largest health-oriented communications network, today announced four of its network agencies were honored at the 2014 MM&M Awards, making Publicis Healthcare the most winning agency network recognized. Additionally, Matt McNally, President, Publicis Health Media, received the Silver Agency Marketer of the Year Award, and Allyson Mariani, Media Planner, Publicis Health Media, was honored with the Gold Young Marketer of the Year Award. PHCG agencies picked up nine MM&M awards, including: Agency Marketer of the Year (Silver MM&M Award): Matt McNally, President, Publicis Health Media Young Marketer of the Year (Gold MM&M Award): Allyson Mariani, Media Planner, Publicis Health Media Best Use of Direct Marketing (Gold MM&M Award): Heartbeat West and Sientra for "Feel So Good" Best Use of Direct Marketing (Silver MM&M Award): Digitas Health LifeBrands and Rebif(R) (interferon beta-1a) by EMD Serono, Inc. and Pfizer Inc for "Rebif Information Kit" Best Branded Website for Healthcare Professionals (Gold MM&M Award): Publicis Life Brands Medicus and Chattem, a Sanofi company for "Nasacort Allergy 24HR Launch Website" Best Use of Social Media (Silver MM&M Award): Heartbeat Ideas, Heartbeat West, and Corcept Therapeutics for "Cushing's Connection" Best Medical Digital Initiative for Consumers (Silver MM&M Award): Heartbeat Ideas, Heartbeat West, and Corcept Therapeutics for "Cushing's Connection" Best Philanthropic Campaign (Gold MM&M Award): Saatchi & Saatchi Wellness and Crossroads Community for "Crossroads Community Street Fare" Best TV Advertising Campaign (Gold MM&M Award): Saatchi & Saatchi Wellness and AbbVie (Humira) for "Inside The Circle"
CORT: 3.43 (+0.03)
Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014
Business Wire - Mon Sep 29, 4:54AM CDT
Cortendo AB (OAX:CORT)
CORT: 3.43 (+0.03)
5 Stocks to Trade for Big Breakout Gains
at The Street - Mon Sep 22, 10:45AM CDT
These stocks look ready to break out and trade higher from current levels.
TSLA: 207.00 (-1.88), FLL: 1.43 (unch), SYRX: 1.10 (unch), GOOGL: 521.51 (-10.60), CORT: 3.43 (+0.03), GSAT: 2.58 (+0.05)
Cortendo AB: Interim Report, Q2 and H1 2014
Business Wire - Tue Aug 26, 2:14AM CDT
Cortendo AB (OSE:CORT)
CORT: 3.43 (+0.03)
Investors look to Lighten Up on Shares of Corcept Therapeutics, Shares Down 8.8% (CORT)
Comtex SmarTrend(R) - Thu Aug 21, 12:42PM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 8.8% to $2.69 on 1.1x average daily volume. Corcept Therapeutics has traded 248,000 shares thus far today, vs. average volume of 226,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's 0.5%) and underperformed the S&P 500 (-8.8% to the S&P's 0.3%) during today's trading.
CORT: 3.43 (+0.03)
Earnings Estimates Moving Higher for Corcept Therapeutics (CORT): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 7:43AM CDT
Corcept Therapeutics could be a solid choice for investors, as it witnessed solid activity on the earnings estimate revision front and also has a favorable Zacks Rank.
CORT: 3.43 (+0.03)
Moving Average Crossover Alert: Corcept Therapeutics (CORT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:27AM CST
Moving Average Crossover Alert: Corcept Therapeutics (CORT)
CORT: 3.43 (+0.03)
Global Cushing's Syndrome Therapeutics Market 2015-2019: Key Vendors are Corcept Therapeutics, HRA Pharma and Novartis
M2 - Thu Nov 20, 5:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvdxbs/global_cushings) has announced the addition of the "Global Cushing's Syndrome Therapeutics Market 2015-2019" report to their offering. One major trend upcoming in this market is the increase in public awareness of Cushing's syndrome. This is expected to lead to an increase in the number of treatment-seeking patients, thereby giving rise to the consumption of medications. According to the report, the major driving factor of the market is the presence of a huge unmet need in this rare disease area. Few FDA-approved drugs are available, and the use of off-label drugs can cause several adverse effects. Thus, drug makers have the opportunity to produce therapies which can give them an edge over others and seize a major portion of the total market. Further, the report states that the adverse effects of the drugs used to treat Cushing's syndrome are a major challenge to the growth of the market. Patient incompatibility leads to an increase in the churn-out rate of the patients from the treatment. This results in restraining the market growth. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Disease Overview 08. Market Landscape 09. Market Segmentation by Class of Drugs 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Form 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Pipeline Portfolio 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Corcept Therapeutics - HRA Pharma - Novartis - Aspireo Pharmaceuticals - Cortendo - ElexoPharm - Ipsen - Isis Pharmaceuticals - Orphagen Pharmaceuticals - Samaritan Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wv...l_cushings
ISIS: 62.32 (+0.45), CORT: 3.43 (+0.03), NVS: 93.52 (-0.82)
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:18PM CST
CORT: 3.43 (+0.03)
Corcept posts 3Q loss
Automated Insights - Tue Nov 04, 5:15PM CST
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported a loss of $6 million in its third quarter.
CORT: 3.43 (+0.03)
Corcept Therapeutics beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:28PM CST
CORT: 3.43 (+0.03)
Corcept Therapeutics Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Marketwired - Tue Nov 04, 3:09PM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today reported its financial results for the quarter ended September 30, 2014. The company also provided an update on its clinical programs and revised its 2014 revenue guidance.
CORT: 3.43 (+0.03)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.26 (-0.13), ITRI: 39.98 (-0.70), AWAY: 30.19 (+0.29), OKE: 44.86 (-0.81), HR: 27.04 (-0.01), NYMT: 7.82 (-0.08), OCLR: 1.89 (-0.01), ENPH: 12.45 (-0.10), ADEP: 8.14 (+0.02), CBSO: 27.51 (+0.58), NSTG: 13.58 (+0.27), MITT: 19.29 (-0.22), CRTO: 38.00 (-0.08), FOXA: 36.90 (-0.22), OKS: 39.41 (-0.11), JMBA: 13.62 (+0.09), IVR: 15.74 (-0.17), CSU: 24.93 (-0.29), MYGN: 33.98 (-1.15), JIVE: 5.76 (-0.09), GAS: 51.18 (-1.43), COUP: 15.00 (-0.27), NRP: 9.22 (-0.37), MOSY: 1.73 (-0.02), COHR: 58.29 (-0.85), DOX: 46.10 (-1.00), CKEC: 26.46 (-0.09), OAS: 12.33 (+1.28), PAYC: 24.46 (-1.18), PCYC: 132.65 (-2.34), AXLL: 38.92 (-2.19), NP: 57.25 (-0.95), BIRT: 6.54 (-0.01), ATVI: 19.90 (-0.44), EXAM: 39.18 (-0.36), P: 17.35 (-0.12), JAZZ: 165.12 (-8.09), PBPB: 12.11 (-0.13), EXEL: 1.40 (unch), CERS: 4.87 (+0.27), DVN: 53.01 (-0.83), FEYE: 29.12 (-0.32), CHUY: 19.81 (+0.34), FRGI: 62.85 (+1.60), GHDX: 32.13 (-0.53), PACD: 4.41 (-0.14), BIO: 117.51 (-1.55), BIOL: 2.74 (+0.06), JKHY: 61.51 (-0.38), KAR: 34.25 (+0.05), CDXS: 2.35 (+0.02), MPO: 1.07 (-0.23), FANG: 52.47 (-0.64), CORT: 3.43 (+0.03), CALD: 15.16 (-0.28)
Corcept reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:56PM CDT
CORT: 3.43 (+0.03)
Corcept Therapeutics to Announce Third Quarter Financial Results and Host Conference Call
Marketwired - Tue Oct 28, 3:08PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT: 3.43 (+0.03)
Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 3.49 (+0.03), AMPE: 3.66 (+0.15), CEMP: 19.00 (+0.47), CORT: 3.43 (+0.03)
Heartbeat Wins 8 New Awards, Including CLIO Silver & MM&M Gold
Business Wire - Mon Oct 13, 11:01AM CDT
Heartbeat Ideas and Heartbeat West, natively-digital, full-service, marketing innovation agencies, have won eight new awards over the last few weeks, bringing to 16 the total number of industry awards in this record-setting year for the company. Heartbeat's honored work includes Corcept Therapeutics' Korlym "Cushing's Connection" Integrated Campaign, XenoPort's HORIZANT "End the Bedtime Battle" Integrated Campaign, and Sientra's "Feel So Good" Online Media Campaign.
CORT: 3.43 (+0.03)
Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:48AM CDT
Esperion Therapeutics has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ESPR: 37.48 (-1.00), AMPE: 3.66 (+0.15), CEMP: 19.00 (+0.47), CORT: 3.43 (+0.03)
PTC Therapeutics (PTCT) Crumbles: Stock Falls by 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:42AM CDT
PTC Therapeutics stock fell over 5% last trading session, continuing its recent downtrend
LCI: 43.58 (-0.46), PTCT: 55.87 (+0.54), CEMP: 19.00 (+0.47), CORT: 3.43 (+0.03)
Publicis Healthcare Agencies and Leaders Honored at the 2014 MM&M Awards
PRWeb - Mon Oct 06, 7:04AM CDT
Publicis Healthcare Communications Group (PHCG), the world's largest health-oriented communications network, today announced four of its network agencies were honored at the 2014 MM&M Awards, making Publicis Healthcare the most winning agency network recognized. Additionally, Matt McNally, President, Publicis Health Media, received the Silver Agency Marketer of the Year Award, and Allyson Mariani, Media Planner, Publicis Health Media, was honored with the Gold Young Marketer of the Year Award. PHCG agencies picked up nine MM&M awards, including: Agency Marketer of the Year (Silver MM&M Award): Matt McNally, President, Publicis Health Media Young Marketer of the Year (Gold MM&M Award): Allyson Mariani, Media Planner, Publicis Health Media Best Use of Direct Marketing (Gold MM&M Award): Heartbeat West and Sientra for "Feel So Good" Best Use of Direct Marketing (Silver MM&M Award): Digitas Health LifeBrands and Rebif(R) (interferon beta-1a) by EMD Serono, Inc. and Pfizer Inc for "Rebif Information Kit" Best Branded Website for Healthcare Professionals (Gold MM&M Award): Publicis Life Brands Medicus and Chattem, a Sanofi company for "Nasacort Allergy 24HR Launch Website" Best Use of Social Media (Silver MM&M Award): Heartbeat Ideas, Heartbeat West, and Corcept Therapeutics for "Cushing's Connection" Best Medical Digital Initiative for Consumers (Silver MM&M Award): Heartbeat Ideas, Heartbeat West, and Corcept Therapeutics for "Cushing's Connection" Best Philanthropic Campaign (Gold MM&M Award): Saatchi & Saatchi Wellness and Crossroads Community for "Crossroads Community Street Fare" Best TV Advertising Campaign (Gold MM&M Award): Saatchi & Saatchi Wellness and AbbVie (Humira) for "Inside The Circle"
CORT: 3.43 (+0.03)
Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014
Business Wire - Mon Sep 29, 4:54AM CDT
Cortendo AB (OAX:CORT)
CORT: 3.43 (+0.03)
5 Stocks to Trade for Big Breakout Gains
at The Street - Mon Sep 22, 10:45AM CDT
These stocks look ready to break out and trade higher from current levels.
TSLA: 207.00 (-1.88), FLL: 1.43 (unch), SYRX: 1.10 (unch), GOOGL: 521.51 (-10.60), CORT: 3.43 (+0.03), GSAT: 2.58 (+0.05)
Cortendo AB: Interim Report, Q2 and H1 2014
Business Wire - Tue Aug 26, 2:14AM CDT
Cortendo AB (OSE:CORT)
CORT: 3.43 (+0.03)
Investors look to Lighten Up on Shares of Corcept Therapeutics, Shares Down 8.8% (CORT)
Comtex SmarTrend(R) - Thu Aug 21, 12:42PM CDT
Corcept Therapeutics (NASDAQ:CORT) is one of today's worst performing low-priced stocks, down 8.8% to $2.69 on 1.1x average daily volume. Corcept Therapeutics has traded 248,000 shares thus far today, vs. average volume of 226,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's 0.5%) and underperformed the S&P 500 (-8.8% to the S&P's 0.3%) during today's trading.
CORT: 3.43 (+0.03)
Earnings Estimates Moving Higher for Corcept Therapeutics (CORT): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 7:43AM CDT
Corcept Therapeutics could be a solid choice for investors, as it witnessed solid activity on the earnings estimate revision front and also has a favorable Zacks Rank.
CORT: 3.43 (+0.03)
